AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02250703
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intranasal dexmedetomidine 2mcg/kg upto maximum dose of 100mcg
Trial: NCT02802267
Drug: Inecalcitol
RxNorm normalized name: Inecalcitol
DrugBank: Inecalcitol (DB04796)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vitamin D receptor agonist
Trial: NCT01474018
Drug: QR-bromocriptine
DrugBank: Bromocriptine (DB01200)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The study drug is added-on to patients on existing type 2 diabetes treatment with insulin +metformin+exercise/nutritional counseling. The study drug is titrated up starting at one 0.8mg tab daily for 1 week, then 2 (0.8mg) tablets for week 2, then 3 tablets for week 3, then 4 tablets for week 4, then 5 tablets for week 5, then six tablets for week 6 (total 4.8). The limiting factor is nausea at which point the patients will back down the highest tolerated dose and continue on that dose for the remainder of the 6 months of the study.
Trial: NCT02820948
Drug: Vitamin E ointment application
RxNorm normalized name: vitamin E Topical Ointment
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Before the skin stapling and after the subcutaneous irrigation with normal saline, sterile Vitamin E acetate ointment was applied in the subcutaneous tissue; 2 ml were applied in the suprapubic incision and 0.5 ml in the rest of port sites.
Trial: NCT00290511
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/m\^2 intravenous (IV) over 5-30 minutes on Days 2-4.
Trial: NCT00290511
Drug: Mitoxantrone
RxNorm normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/m\^2 IV over 5-30 minutes on Day 2.
Trial: NCT00290511
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m\^2 IV over 4-6 hours on Day 1 and 8; maintenance Rituximab = 375 mg/m\^2 IV over 4-6 hours on Day 1 only, a single dose every other month for 12 months (6 doses total).
Trial: NCT00290511
Drug: Zevalin
RxNorm normalized name: Zevalin KIT
DrugBank: Ibritumomab tiuxetan (DB00078)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 0.3 mCi/kg IV after 4 cycles of R-FND.
Trial: NCT00290511
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 20 mg by mouth (PO) or IV daily on Days 2-6.
Trial: NCT00124709
Drug: Pimecrolimus
RxNorm normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimecrolimus cream 1 %
Trial: NCT00122954
Drug: Fish oil concentrate
RxNorm normalized name: Fish Oil Concentrate
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fish oil concentrate at a daily dose of 6 grams (2.1 gram EPA and 1.5 gram DHA).
Trial: NCT00096317
Drug: ixabepilone
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00096317
Drug: ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00830297
Drug: Insulatard (long-acting insulin)
RxNorm normalized name: insulin isophane, human Injectable Suspension [Human Insulatard]
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In group No.1 (study arm 1 (=A)), patients will be treated with long-acting insulin (Insulatard) as soon as the glucose-level before supper surpasses 140 mg/dl. The normoglycemic goal in this group will be from 110 to 120 mg/dl.
Trial: NCT00830297
Drug: Conventional
RxNorm normalized name: PECTIN 11.5 mg in 7 g ORAL LOZENGE [Lolleez Birthday Cake - Conventional]
DrugBank: Pectin (DB11158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In group No.2 (study arm 2 (=B)), patients will be treated conventionally according to the decisions taken by the physicians on the ward. The following suggestions will be brought to the attention of the ward in order to standardize the treatment of the patients in study arm B: 1. Treatment in this group should be initiated if the fasting glucose level surpasses the renal glucose threshold, i.e. 180 mg/dl. 2. As the proposed life-style modifications for the treatment of NODAT1 are not feasible during this very early post-transplant phase, the basis of the conventional therapy will be proposed to be sulfonyl urea drugs (i.e. Gliclazide - Diamicron®, 30 mg, not more than twice daily). 3. Short-acting insulin will be strongly recommended to be used for corrections of capillary blood glucose levels above 250 mg/dl.
Trial: NCT02292069
Drug: Amlodipine besylate/Atorvastatin calcium
RxNorm normalized name: Amlodipine Besylate/Atorvastatin Calcium 5 MG-80 MG Oral Tablet
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine besylate/Atorvastatin calcium 10/80 mg
Trial: NCT04625517
Drug: Low Osmolar Contrast Material, 300-399 Mg/Ml Iodine Concentration, Per Ml
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injection of low osmolar contrast material during the digital mammography exam
Trial: NCT01695759
Drug: Epoetin alpha
RxNorm normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eritromax), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.
Trial: NCT00077129
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00077129
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02619162
Drug: Nintedanib
RxNorm normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets of 100 mg. or 150 mg.
Trial: NCT01638260
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide once daily 1.8 mg injection subcutaneously, 26 weeks
Trial: NCT02619162
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet of 2.5 mg.
Trial: NCT03108846
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-15 mg/day (target: 15mg/day if tolerated)
Trial: NCT03310957
Drug: ladiratuzumab vedotin
RxNorm normalized name: Ladiratuzumab vedotin
DrugBank: Ladiratuzumab vedotin (DB15409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given into the vein (IV; intravenously)
Trial: NCT03310957
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion every 3 weeks
Trial: NCT02835079
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00889161
Drug: Curcumin
RxNorm normalized name: Curcumin
DrugBank: Curcumin (DB11672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dosage of 500mg twice a day for 3 weeks. Using the forced dose titration design, dose will be titrated up to 1g twice a day at Week 3 for a total of three weeks and then titrated again to 2g twice a day at Week 6 for three weeks.
Trial: NCT00888732
Drug: Insulin Aspart, BIAsp 70, BIAsp50, Human Insulin
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.2 U/IU/kg subcutaneous injection, single dose
Trial: NCT01612832
Drug: Pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients in one group will receive 150 mg of PGL at 20:00 h the night before surgery and at 1.5 h before surgery, and will undergo surgery under general anesthesia (GA).
Trial: NCT02961101
Drug: Anti-PD-1 antibody
RxNorm normalized name: Monoclonal antibody anti-SSEA-1
DrugBank: Fanolesomab (DB14211)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-PD-1 antibody will be given at 1-3mg/kg on day8 by IV every three weeks
Trial: NCT02961101
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine will be given at 10mg/d on day 1to 5 by IV every three weeks
Trial: NCT00923611
Drug: Fimasartan
RxNorm normalized name: Fimasartan
DrugBank: Fimasartan (DB09279)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00520806
Drug: Relaxin
RxNorm normalized name: Relaxin
DrugBank: Serelaxin (DB05794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion for 48 h at 30 ug/kg/day
Trial: NCT04276376
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fc-engineered, humanized, Ig G1 monoclonal antibody against PDL-1 1200mg q3w
Trial: NCT04276376
Drug: Rucaparib
RxNorm normalized name: Rucaparib
DrugBank: Rucaparib (DB12332)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inhibitor of poly-adenosine diphosphate \[ADP\] ribose polymerase (PARP) 600mg BID
Trial: NCT03152929
Drug: Paravertebral Block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20-30 mL 0.5% Ropivacaine
Trial: NCT04074967
Drug: Phase Ib ARRY-614 + nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ARRY-614 continuously in 4-week cycles (± 3 days). Nivolumab will be dosed according to FDA-approved dosing schedule.
Trial: NCT04074967
Drug: Phase Ib ARRY-614 + nivolumab+ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ARRY-614 continuously in 4-week cycles (± 3 days). Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule.
Trial: NCT04074967
Drug: Phase II ARRY-614 + nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule.
Trial: NCT04074967
Drug: Phase II ARRY-614 + nivolumab+ipilimumab (melanoma)
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule.
Trial: NCT04074967
Drug: Phase II ARRY-614 + nivolumab+ipilimumab (RCC)
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recommended Phase II dose of ARRY-614 (to be determined) daily in 4-week cycles (± 3 days).~Nivolumab will be dosed according to FDA-approved dosing schedule. Ipilimumab therapy will be dosed according to FDA-approved dosing schedule.
Trial: NCT01728376
Drug: Daptomycin
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous daptomycin given at 7 mg/kg (ages 12-17 years); 9 mg/kg (ages 7-11 years); 12 mg/kg (ages 1-6 years) infused once daily, intravenously, over 30 or 60 minutes. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
Trial: NCT01035229
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus (labeled as RAD001) was formulated as tablets of 2.5 mg strength and blisterpacked in units of 10 tablets.
Trial: NCT01035229
Drug: Everolimus Placebo
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus Placebo matched to the everolimus 2.5 mg tablet strength was blister-packed in units of 10 tablets. Matching placebo tablets were formulated to be indistinguishable from the everolimus tablets. Everolimus placebo was taken as a daily oral dose of 7.5 mg and was defined as the control drug.
Trial: NCT03152929
Drug: Pectoral Nerve Block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20-30 mL 0.5% Ropivacaine
Trial: NCT04303065
Drug: Dexamethasone Oral
RxNorm normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: It will be a short and descending course of oral dexamethasone: 4mg/6 hours (2 days); 4 mg/8 hours (2 days); 2 mg/6 hours (2 days); 2 mg/8 hours (2 days); 1 mg/8 hours (2 days); 1 mg/12 hours (2 days).
Trial: NCT00947167
Drug: pertuzumab
RxNorm normalized name: Pertuzumab
DrugBank: Pertuzumab (DB06366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 840 mg, 420 mg, iv
Trial: NCT00947167
Drug: erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg, PO
Trial: NCT02657408
Drug: BI 1026706
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01009073
Drug: erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150 mg of erlotinib is taken orally once daily.
Trial: NCT01009073
Drug: irinotecan (3-week schedule)
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 180 mg/m2 over 90 minutes, irinotecan will be given by intravenous infusion on Day 1 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed.
Trial: NCT01009073
Drug: irinotecan (weekly schedule)
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 75 mg/m2 over 45 minutes, irinotecan will be given by intravenous infusion on Days 1 and 8 of each 21 day cycle.~Note - The dose and schedule is subject to change based on the toxicities observed.
Trial: NCT03764293
Drug: SHR-1210
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive SHR-1210 intravenously, Dosage form: lyophilised powder, Strength: 200 mg /vial
Trial: NCT03764293
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects receive Apatinib orally, Dosage form: tablet, Strength: 250 mg/tablet
Trial: NCT03764293
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects receive Sorafenib orally, Dosage form: tablet, Strength: 0.2 g/tablet
Trial: NCT00080899
Drug: fenretinide
RxNorm normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT04044001
Drug: BTZ-043
RxNorm normalized name: BTZ-043
DrugBank: BTZ-043 (DB17737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTZ-043 (250mg per tablet)
Trial: NCT04044001
Drug: Probe Drug Cocktail
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A probe drug cocktail will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally. The probe drug cocktail consists of~* Caffeine: 1 tablet à 150mg~* Tolbutamide: 1/4 tablet à 500mg~* Dextromethorphan: 10 ml syrup à 15mg/5ml~* Midazolam:2 ml solution à 5mg/5ml~* Digoxin: 2 tablets à 0.25mg
Trial: NCT04044001
Drug: Dolutegravir 50mg Tab
RxNorm normalized name: DOLUTEGRAVIR 50MG TAB
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 tablet à 50mg Dolutegravir will be given to randomly selected patients after inclusion on Day 1 and on Day 14 once orally.
Trial: NCT00296192
Drug: Rotigotine nasal spray
RxNorm normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rotigotine- HCl 2.5mg/mL nasal spray, dosage per puff of 275µg per 110µg administered in up to 4 deliveries
Trial: NCT01231880
Drug: Four monthly IPT with dihydroartemisinin Piperaquine (DP)
RxNorm normalized name: .alpha.-dihydroartemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given every 4 months (once a school term)
Trial: NCT01231880
Drug: Monthly IPT using DP
RxNorm normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given every month
Trial: NCT00253162
Drug: risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00329797
Drug: LHRH
RxNorm normalized name: LHRH - Luteinizing hormone releasing hormone
DrugBank: Lutein (DB00137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LHRH therapy must take place for a minimum of one year. Choice of LHRH agonist, dose, and duration are at the discretion of the treating physician.
Trial: NCT03791099
Drug: Metronidazole
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After subgingival ultrasonic scaling is performed, metronidazole in polymer matrix is applied to the selected periodontal pockets.
Trial: NCT02495974
Drug: enzalutamide
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral
Trial: NCT04490915
Drug: Crinecerfont
RxNorm normalized name: Crinecerfont
DrugBank: Crinecerfont (DB18518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRF type 1 receptor antagonist
Trial: NCT00511368
Drug: Bevirimat
RxNorm normalized name: Bevirimat
DrugBank: Bevirimat (DB06581)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02791763
Drug: 1 to 4 mg tablets of GSK1278863
RxNorm normalized name: afamelanotide
DrugBank: Afamelanotide (DB04931)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 7.0 millimeters (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of GSK1278863 as active ingredient, to be orally administered once daily.
Trial: NCT02791763
Drug: Epoetin beta pegol
RxNorm normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: An injectable formulation containing 25 micrograms µg, 50 µg, 75 µg, 100 µg, 150 µg, 200 µg, or 250 µg of epoetin beta pegol per syringe (0.3 mL), supplied as a glass syringe prefilled with epoetin beta pegol solution (clear colorless to pale yellow). Epoetin beta pegol will be subcutaneously administered once every 2 or 4 weeks.
Trial: NCT02048319
Drug: Pasireotide LAR 60 mg
RxNorm normalized name: pasireotide LAR 60 MG Injection
DrugBank: Pasireotide (DB06663)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pasireotide long acting release, intramuscular injection
Trial: NCT04383418
Drug: dexmedetomidine nasal spray
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexmedetomidine nasal spray
Trial: NCT04383418
Drug: dexmedetomidine hydrochloride nasal spray blank preparation
RxNorm normalized name: Dexmedetomidine Hydrochloride
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexmedetomidine hydrochloride nasal spray blank preparation
Trial: NCT01929811
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin: 500mg tid, orally (500mg daily in first cycle) on day 1 to day 21 of each 21 day cycle
Trial: NCT01929811
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
Trial: NCT01929811
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
Trial: NCT01929811
Drug: cyclophosphomide
DrugBank: Cyclo(his-pro) (DB02414)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
Trial: NCT01456897
Drug: OPC-34712
RxNorm normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orally administered once daily
Trial: NCT04655170
Drug: Revefenacin (YUPELRI) & Formoterol (Perforomist)
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Revefenacin is a Long-acting anticholinergics (LAMAs) and Formoterol is Long-acting bronchodilators, beta-agonists (LABAs).
Trial: NCT04655170
Drug: Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic)
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albuterol Inhalation Aerosol (short-acting beta-agonists) \& Ipratropium Aerosol (short-acting anticholinergic)
Trial: NCT00604760
Drug: MEM 3454
RxNorm normalized name: MEM 1003
DrugBank: MEM 1003 (DB05547)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule 5 mg once a day
Trial: NCT00604760
Drug: MEM 3454
RxNorm normalized name: MEM 1003
DrugBank: MEM 1003 (DB05547)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule 15 mg once a day
Trial: NCT00604760
Drug: MEM 3454
RxNorm normalized name: MEM 1003
DrugBank: MEM 1003 (DB05547)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule 50 mg once a day
Trial: NCT00770159
Drug: odanacatib
RxNorm normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panel A: MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: MK0822 tablets 100 mg once weekly for 6 weeks.
Trial: NCT00302068
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline (Zoloft), daily, for 16 weeks.